Deadline for manuscript submissions: 31 December 2020Print Special Issue Flyer (19)
Department of Neurology, Hospital Universitario MIguel Servet, Zaragoza, Spain
Interests: Neuroscience, Emergency medicine, Psychology, Immunology and microbiology, Nursing, Biochemistry, Genetics and molecular Biology
Despite the advances achieved in the treatment of acute ischemic stroke, it is still a world-wide leading cause of mortality and disability. Intravenous thrombolysis has been considered the standard care since two clinical trials demonstrated efficacy of r-TPA, the NINDS and ECASS II trials, when administered within the first 3 hours after stroke onset. The time window was extended to 4 and a half hours after the ECASS III trial was completed, and up to six hours in the IST-3 trial, given that the benefit was significant. Two major draw-backs have been claimed: the risk of brain hemorrhage in around 6% of eligible patients and the low rate of recanalization. Mechanical thrombectomy after thrombolysis or thrombectomy alone improve outcomes and increase recanalization rates, with a longer time window in patients with salvageable tissue and large vessel occlusion. Recanalization is quite relevant is because a postitive association was found between recanalization and functional improvement. A meta-analysis from five clinical trials and 1287 patients included within 12 hours from stroke onset, there was a clear benefit of endovascular thrombectomy plus medical therapy compared with the control group of medical therapy alone in terms of 90 day-disability. In another meta-analysis from the same trials it was concluded that for every hour delay of thrombectomy was associated with less favorable outcomes (OR: 0.84; 95% CI: 0.76-0.93). In the DEFUSE 3 trial 182 patients with ischemic stroke and large-vessel occlusion, selected by perfusion mismatch, were randomised to receive either thrombectomy plus medical standard treatment or medical treatment alone within 6-12 hours from stroke onset. The trial was stopped prematurely because of the benefit of thrombectomy on functional outcome Furthermore the DAWN trial recruited 206 stroke patients within 24 hour-window, and with mismatch between infarct volume and clinical deficit with significant improvement. No differences were seen in terms of mortality and brain hemorrhage between thrombectomy and medical treatment alone. Telemedicine is of help to hasten the process of patient selection for the appropriate treatment in areas without thrombectomy-capable medical centers. Mobile stroke units may be an option to provide the first care in determined areas.
The advances in the management of acute ischemic stroke should not be a hamper for primary prevention strategies. Early detection and control of risk factors is essential for health purposes and to decrease the burden for health care systems. However, there is a significant proportion of ischemic strokes of undetermined cause (>30% of cases), for which no preventive action can be undertaken.
Ischemic stroke management, Trials, Endovascular thrombectomy
Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Signa Viate is an international peer-reviewed open access semi-annual journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Science Citation Index Expanded (SciSearch) The Science Citation Index (SCI) is a citation index originally produced by the Institute for Scientific Information (ISI) and created by Eugene Garfield. It (Science Citation Index Expanded) covers more than 8,500 notable and significant journals, across 150 disciplines in science and technology, from 1900 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.